Results 101 to 110 of about 8,933 (160)

Dabigatran etexilate for preventing stroke in patients with non-valvular atrial fibrillation - results from daily application

, 2014
Primjena dabigatran-eteksilata u bolesnika koji boluju od nevalvularne atrijske fibrilacije u svrhu sprječavanja tromboembolijskih incidenata inicijalno je ohrabrena vrlo povoljnim rezultatima učinkovitosti i sigurnosti iz pivotalne kliničke studije RE ...
Počanić, Darko
core   +1 more source

Anticoagulation With Dabigatran: When to Worry

, 2015
Dabigatran etexilate is the prodrug of dabigatran, a direct thrombin inhibitor that is used to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and to prevent and treat venous thromboembolism (VTE)
Singh-Franco, Devada
core  

New options with dabigatran etexilate in anticoagulant therapy

Vascular Health and Risk Management, 2010
Lars Maegdefessel, Joshua M Spin, Junya Azuma, Philip S TsaoDepartment of Cardiovascular Medicine, Stanford University – School of Medicine, Stanford, CA, USAAbstract: Thrombosis, the localized clotting of blood, occurs in both the arterial and
Lars Maegdefessel, Joshua M Spin, Junya Azuma, et al   +3 more
doaj  

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. [PDF]

Eur J Drug Metab Pharmacokinet, 2020
Duan J, Duan J, Yang L, Li H, Yamamura N, Harada A.   +5 more
europepmc   +1 more source

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate

Patient Preference and Adherence, 2009
L Bellamy1, N Rosencher1, BI Eriksson21Anaesthesiology Department, Hôpital Cochin (AP-HP), René Descartes University, Paris 75014 France; 2Orthopaedic Department, University Hospital Sahlgrenska/Ostra, Gothenburg, SwedenAbstract: The
L Bellamy, N Rosencher, BI Eriksson
doaj  

A Phase 1 Study to Assess the Effect of Fruquintinib on the Pharmacokinetics of P‐gp and BCRP Substrates in Healthy Subjects

Clinical and Translational Science
Fruquintinib, a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (−1, −2, and −3), is approved for previously treated metastatic colorectal cancer.
Martha Gonzalez, Zhao Yang, William R. Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
doaj   +1 more source

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling. [PDF]

Sci Rep, 2020
Wang N, Chen L, Li N, Xu G, Qi F, Zhu L, Liu W.   +6 more
europepmc   +1 more source

Moxifloxacin-Mediated Downregulation of Intestinal P-Glycoprotein Alters the Pharmacokinetics of Dabigatran Etexilate: Mechanistic Insights in Rats and PBPK Model-Informed Dose Optimization. [PDF]

Pharmaceutics
Qu Y, Yang Z, Ma W, Xiao P, Gu Y, Pan J, Zhang X, Zhao C, Yu Y.   +8 more
europepmc   +1 more source